FDA Inspection 1050979 — Alnylam Pharmaceuticals, Inc.
The FDA completed an inspection of Alnylam Pharmaceuticals, Inc. on April 25, 2018 in Cambridge, MA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- April 25, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cambridge, MA (United States)
Additional Details
Sponsor, Contract Research Organization